Filana Therapeutics, Inc. filed a Form 8-K on November 12, 2026, disclosing the appointment of Jill M. Quigley to its Board of Directors, effective November 8, 2026.

Key Highlights

  • New director appointed: Jill M. Quigley was appointed to the Filana Therapeutics Board of Directors effective November 8, 2026.
  • Class I designation: Ms. Quigley was appointed as a Class I director, with a term expiring at the Company's 2028 annual meeting of stockholders.
  • No committee assignments: According to the filing, Ms. Quigley has not been appointed to any committees of the Board.
  • No prior arrangements: The filing states there are no arrangements or understandings between Ms. Quigley and any other person pursuant to which she was appointed.
  • Compensation eligibility: Upon appointment, Ms. Quigley will be eligible to participate in future compensation to independent directors, as awarded from time to time.

Jill M. Quigley Joins Filana Therapeutics Board as Class I Director

Filana Therapeutics, Inc. (NASDAQ:FLNA) reported in an 8-K filed November 12, 2026, that its Board of Directors appointed Jill M. Quigley as a Class I director, with the appointment effective November 8, 2026. According to the filing, Ms. Quigley's term is set to expire at the Company's 2028 annual meeting of stockholders.

The filing disclosed that Ms. Quigley has not been assigned to any Board committees at the time of appointment. The company stated that there are no arrangements or understandings between Ms. Quigley and any other person in connection with her appointment, and that she "does not have direct or indirect material interests in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K."

With respect to compensation, the filing noted that Ms. Quigley will be eligible to participate in future compensation extended to independent directors "as awarded from time to time." The company also attached a press release dated November 11, 2026, as Exhibit 99.1 announcing the appointment, which was furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The 8-K was signed by Eric J. Schoen, Chief Financial Officer of Filana Therapeutics, Inc.

What Was Disclosed

Filana Therapeutics disclosed the appointment of Jill M. Quigley as a Class I director effective November 8, 2026, with a term running to the 2028 annual meeting, no committee assignments, no prior arrangements, and eligibility for future independent director compensation.